$17.47 Million in Sales Expected for Global Blood Therapeutics Inc (NASDAQ:GBT) This Quarter

Wall Street analysts forecast that Global Blood Therapeutics Inc (NASDAQ:GBT) will announce sales of $17.47 million for the current quarter, Zacks reports. Eight analysts have provided estimates for Global Blood Therapeutics’ earnings, with the highest sales estimate coming in at $20.66 million and the lowest estimate coming in at $4.24 million. The company is expected to report its next quarterly earnings results on Wednesday, August 5th.

According to Zacks, analysts expect that Global Blood Therapeutics will report full-year sales of $87.59 million for the current financial year, with estimates ranging from $32.12 million to $109.43 million. For the next year, analysts forecast that the firm will post sales of $222.21 million, with estimates ranging from $70.93 million to $304.55 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Global Blood Therapeutics.

Global Blood Therapeutics (NASDAQ:GBT) last released its earnings results on Wednesday, May 6th. The company reported ($1.20) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.47) by $0.27. The company had revenue of $14.12 million for the quarter, compared to the consensus estimate of $3.65 million. During the same period in the prior year, the company earned ($0.87) earnings per share.

Several research analysts recently commented on the stock. Oppenheimer reaffirmed a “buy” rating and issued a $101.00 price objective on shares of Global Blood Therapeutics in a report on Monday, June 15th. Canaccord Genuity reaffirmed a “hold” rating on shares of Global Blood Therapeutics in a report on Thursday, June 25th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Global Blood Therapeutics in a report on Friday, June 12th. Goldman Sachs Group raised shares of Global Blood Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $91.00 to $103.00 in a report on Wednesday. Finally, Morgan Stanley raised their price objective on shares of Global Blood Therapeutics from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the company. Global Blood Therapeutics has an average rating of “Buy” and a consensus target price of $105.00.

Shares of Global Blood Therapeutics stock traded down $2.61 on Friday, reaching $67.83. 844,737 shares of the company traded hands, compared to its average volume of 1,201,523. The company has a 50 day moving average of $67.49 and a 200 day moving average of $69.04. The firm has a market capitalization of $4.13 billion, a PE ratio of -13.93 and a beta of 1.89. Global Blood Therapeutics has a 52 week low of $39.95 and a 52 week high of $87.54. The company has a debt-to-equity ratio of 0.30, a current ratio of 9.07 and a quick ratio of 8.83.

In related news, Director Dawn Svoronos sold 2,544 shares of Global Blood Therapeutics stock in a transaction on Friday, June 19th. The shares were sold at an average price of $63.94, for a total value of $162,663.36. Following the transaction, the director now owns 4,800 shares in the company, valued at approximately $306,912. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Ted W. Love sold 2,817 shares of Global Blood Therapeutics stock in a transaction on Monday, April 27th. The stock was sold at an average price of $80.87, for a total transaction of $227,810.79. Following the completion of the transaction, the insider now owns 1,076,150 shares in the company, valued at approximately $87,028,250.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 81,330 shares of company stock worth $6,120,196. 4.30% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the business. Perceptive Advisors LLC grew its holdings in Global Blood Therapeutics by 3.4% in the 1st quarter. Perceptive Advisors LLC now owns 6,065,726 shares of the company’s stock worth $309,897,000 after acquiring an additional 200,000 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Global Blood Therapeutics by 32.5% during the 4th quarter. Bank of America Corp DE now owns 4,712,986 shares of the company’s stock valued at $374,635,000 after purchasing an additional 1,156,164 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Global Blood Therapeutics by 51.9% during the 1st quarter. Janus Henderson Group PLC now owns 4,553,981 shares of the company’s stock valued at $232,662,000 after purchasing an additional 1,555,086 shares in the last quarter. State Street Corp boosted its stake in shares of Global Blood Therapeutics by 1.4% during the 1st quarter. State Street Corp now owns 2,187,383 shares of the company’s stock valued at $111,753,000 after purchasing an additional 29,555 shares in the last quarter. Finally, Capital World Investors boosted its stake in shares of Global Blood Therapeutics by 210.7% during the 1st quarter. Capital World Investors now owns 1,452,448 shares of the company’s stock valued at $74,206,000 after purchasing an additional 984,928 shares in the last quarter.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Featured Story: What is a SEC Filing?

Get a free copy of the Zacks research report on Global Blood Therapeutics (GBT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.